Ivermectin is currently being explored in clinical trials for its anticancer properties. Research suggests that it may inhibit tumor growth, induce apoptosis in cancer cells, and enhance immune responses. Notably, a Phase I/II study is evaluating ivermectin in combination with pembrolizumab for metastatic triple-negative breast cancer, aiming to "turn cold tumors hot" by increasing T-cell infiltration.